The New York Times Health Section has recently published an article on the debate regarding what the appropriate treatment response should be for the discovery of micrometastatic lymph node involvement in a cancer patient. Doctors have long used lymph node status as an important indicator of patient stage and overall prognosis, as the discovery of cancer cells in lymph nodes means that the cancer could have spread beyond the local region in which primary site tumors were initially found. If cancer cells are found in a patient’s lymph nodes, doctors have traditionally re-staged the patient to a more serious status level in recognition of this possibility of metastatic spread. However, our ability to identify individual cancer cells has advanced to such a degree that doctors find themselves in the difficult position of having to interpret the meaning of very small levels of cancer in the lymph nodes. These small levels are known as micrometastases and the debate surrounding them is one of the most pressing in current cancer research. The debate has been especially active in breast cancer treatment, but all forms of cancer have the potential to metastasize to distant locations in the body, so the issue of micrometastases is likely to be one faced by all cancer patients at some point.

The central question in the debate is “What do these small levels mean,” but there aren’t any answers to this question yet. Even though scientists have been aware of the phenomenon of micrometastases for years, it is only with the technological advances in recent years that doctors have been confronted with how to respond—if at all—to these small levels, so there isn’t any historical guidance on what constitutes a “proper response” to them. A few studies have been done, but most of them demonstrate methodological problems that limit the scope of their conclusions, so much more work is still necessary before any firm conclusions can be drawn. The article notes that two long-term studies are currently underway, but their results will not be available for a few years, so this is a question that will be with us for a while.

Whether the issue is breast cancer or one of the major forms of mesothelioma, such as pleural mesothelioma or peritoneal mesothelioma, doctors will have to determine the meaning to the question of “what is the proper response to micrometastatic lymph node involvement” one patient at a time.

Labels: mesothelioma